Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2007 1
2008 1
2014 1
2016 1
2017 1
2019 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Phase 1 Lymfactin® Study: 24-month Efficacy and Safety Results of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema.
Leppäpuska IM, Hartiala P, Suominen S, Suominen E, Kaartinen I, Mäki M, Seppänen M, Kiiski J, Viitanen T, Lahdenperä O, Vuolanto A, Alitalo K, Saarikko AM. Leppäpuska IM, et al. Among authors: vuolanto a. J Plast Reconstr Aesthet Surg. 2022 Nov;75(11):3938-3945. doi: 10.1016/j.bjps.2022.08.011. Epub 2022 Aug 17. J Plast Reconstr Aesthet Surg. 2022. PMID: 36151039 Free article. Clinical Trial.
Bioreactor for solid-state cultivation of Phlebiopsis gigantea.
Virtanen V, Nyyssölä A, Vuolanto A, Leisola M, Seiskari P. Virtanen V, et al. Among authors: vuolanto a. Biotechnol Lett. 2008 Feb;30(2):253-8. doi: 10.1007/s10529-007-9538-8. Epub 2007 Sep 22. Biotechnol Lett. 2008. PMID: 17891458
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.
Kuryk L, Vassilev L, Ranki T, Hemminki A, Karioja-Kallio A, Levälampi O, Vuolanto A, Cerullo V, Pesonen S. Kuryk L, et al. Among authors: vuolanto a. PLoS One. 2017 Aug 10;12(8):e0182715. doi: 10.1371/journal.pone.0182715. eCollection 2017. PLoS One. 2017. PMID: 28796812 Free PMC article.
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization.
Ranki T, Joensuu T, Jäger E, Karbach J, Wahle C, Kairemo K, Alanko T, Partanen K, Turkki R, Linder N, Lundin J, Ristimäki A, Kankainen M, Hemminki A, Backman C, Dienel K, von Euler M, Haavisto E, Hakonen T, Juhila J, Jaderberg M, Priha P, Vassilev L, Vuolanto A, Pesonen S. Ranki T, et al. Among authors: vuolanto a. Oncoimmunology. 2014 Dec 15;3(10):e958937. doi: 10.4161/21624011.2014.958937. eCollection 2014 Nov. Oncoimmunology. 2014. PMID: 25941579 Free PMC article.
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.
Ranki T, Pesonen S, Hemminki A, Partanen K, Kairemo K, Alanko T, Lundin J, Linder N, Turkki R, Ristimäki A, Jäger E, Karbach J, Wahle C, Kankainen M, Backman C, von Euler M, Haavisto E, Hakonen T, Heiskanen R, Jaderberg M, Juhila J, Priha P, Suoranta L, Vassilev L, Vuolanto A, Joensuu T. Ranki T, et al. Among authors: vuolanto a. J Immunother Cancer. 2016 Mar 15;4:17. doi: 10.1186/s40425-016-0121-5. eCollection 2016. J Immunother Cancer. 2016. PMID: 26981247 Free PMC article.